Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients

Betti Giusti, Anna Maria Gori, Rossella Marcucci, Claudia Saracini, Ilaria Sestini, Rita Paniccia, Serafina Valente, Davide Antoniucci, Rosanna Abbate, Gian Franco Gensini

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment. BACKGROUND: Residual platelet reactivity (RPR) phenomenon on antiplatelet therapy requires clarification. P2Y12 T744C, CYP3A4 IVS10+12G/A and, in healthy individuals only, CYP2C19*2 polymorphisms have been investigated; however, the influence on platelet reactivity in a large population of high-risk vascular patients on dual antiplatelet treatment has not yet been elucidated. METHODS: A total of 1419 acute coronary syndrome patients on dual antiplatelet treatment were studied. Platelet function was evaluated by platelet-rich plasma aggregation. Electronic nanochips and restriction-fragment length polymorphism were used for analysis of polymorphisms. RESULTS: Only CYP2C19*2, out of the three investigated polymorphisms, is associated with higher platelet reactivity. Carriers of the *2 allele had significantly higher platelet aggregation values after arachidonic acid (AA; P=0.043), 2 μmol/l adenosine 5′ diphosphate (ADP; P

Original languageEnglish
Pages (from-to)1057-1064
Number of pages8
JournalPharmacogenetics and Genomics
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System
Blood Vessels
Blood Platelets
clopidogrel
Acute Coronary Syndrome
Adenosine Diphosphate
Therapeutics
Platelet-Rich Plasma
Platelet Aggregation
Arachidonic Acid
Restriction Fragment Length Polymorphisms
Alleles
Population
Cytochrome P-450 CYP2C19

Keywords

  • Acute coronary syndrome
  • ADP receptor P2Y
  • Cytochrome P450
  • Dual antiplatelet treatment
  • Pharmacogenetics
  • Polymorphism
  • Residual platelet reactivity

ASJC Scopus subject areas

  • Genetics
  • Pharmacology

Cite this

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. / Giusti, Betti; Gori, Anna Maria; Marcucci, Rossella; Saracini, Claudia; Sestini, Ilaria; Paniccia, Rita; Valente, Serafina; Antoniucci, Davide; Abbate, Rosanna; Gensini, Gian Franco.

In: Pharmacogenetics and Genomics, Vol. 17, No. 12, 12.2007, p. 1057-1064.

Research output: Contribution to journalArticle

Giusti, Betti ; Gori, Anna Maria ; Marcucci, Rossella ; Saracini, Claudia ; Sestini, Ilaria ; Paniccia, Rita ; Valente, Serafina ; Antoniucci, Davide ; Abbate, Rosanna ; Gensini, Gian Franco. / Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. In: Pharmacogenetics and Genomics. 2007 ; Vol. 17, No. 12. pp. 1057-1064.
@article{b7fb684083104332afb800af9c10ceab,
title = "Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients",
abstract = "OBJECTIVES: The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment. BACKGROUND: Residual platelet reactivity (RPR) phenomenon on antiplatelet therapy requires clarification. P2Y12 T744C, CYP3A4 IVS10+12G/A and, in healthy individuals only, CYP2C19*2 polymorphisms have been investigated; however, the influence on platelet reactivity in a large population of high-risk vascular patients on dual antiplatelet treatment has not yet been elucidated. METHODS: A total of 1419 acute coronary syndrome patients on dual antiplatelet treatment were studied. Platelet function was evaluated by platelet-rich plasma aggregation. Electronic nanochips and restriction-fragment length polymorphism were used for analysis of polymorphisms. RESULTS: Only CYP2C19*2, out of the three investigated polymorphisms, is associated with higher platelet reactivity. Carriers of the *2 allele had significantly higher platelet aggregation values after arachidonic acid (AA; P=0.043), 2 μmol/l adenosine 5′ diphosphate (ADP; P",
keywords = "Acute coronary syndrome, ADP receptor P2Y, Cytochrome P450, Dual antiplatelet treatment, Pharmacogenetics, Polymorphism, Residual platelet reactivity",
author = "Betti Giusti and Gori, {Anna Maria} and Rossella Marcucci and Claudia Saracini and Ilaria Sestini and Rita Paniccia and Serafina Valente and Davide Antoniucci and Rosanna Abbate and Gensini, {Gian Franco}",
year = "2007",
month = "12",
doi = "10.1097/FPC.0b013e3282f1b2be",
language = "English",
volume = "17",
pages = "1057--1064",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients

AU - Giusti, Betti

AU - Gori, Anna Maria

AU - Marcucci, Rossella

AU - Saracini, Claudia

AU - Sestini, Ilaria

AU - Paniccia, Rita

AU - Valente, Serafina

AU - Antoniucci, Davide

AU - Abbate, Rosanna

AU - Gensini, Gian Franco

PY - 2007/12

Y1 - 2007/12

N2 - OBJECTIVES: The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment. BACKGROUND: Residual platelet reactivity (RPR) phenomenon on antiplatelet therapy requires clarification. P2Y12 T744C, CYP3A4 IVS10+12G/A and, in healthy individuals only, CYP2C19*2 polymorphisms have been investigated; however, the influence on platelet reactivity in a large population of high-risk vascular patients on dual antiplatelet treatment has not yet been elucidated. METHODS: A total of 1419 acute coronary syndrome patients on dual antiplatelet treatment were studied. Platelet function was evaluated by platelet-rich plasma aggregation. Electronic nanochips and restriction-fragment length polymorphism were used for analysis of polymorphisms. RESULTS: Only CYP2C19*2, out of the three investigated polymorphisms, is associated with higher platelet reactivity. Carriers of the *2 allele had significantly higher platelet aggregation values after arachidonic acid (AA; P=0.043), 2 μmol/l adenosine 5′ diphosphate (ADP; P

AB - OBJECTIVES: The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment. BACKGROUND: Residual platelet reactivity (RPR) phenomenon on antiplatelet therapy requires clarification. P2Y12 T744C, CYP3A4 IVS10+12G/A and, in healthy individuals only, CYP2C19*2 polymorphisms have been investigated; however, the influence on platelet reactivity in a large population of high-risk vascular patients on dual antiplatelet treatment has not yet been elucidated. METHODS: A total of 1419 acute coronary syndrome patients on dual antiplatelet treatment were studied. Platelet function was evaluated by platelet-rich plasma aggregation. Electronic nanochips and restriction-fragment length polymorphism were used for analysis of polymorphisms. RESULTS: Only CYP2C19*2, out of the three investigated polymorphisms, is associated with higher platelet reactivity. Carriers of the *2 allele had significantly higher platelet aggregation values after arachidonic acid (AA; P=0.043), 2 μmol/l adenosine 5′ diphosphate (ADP; P

KW - Acute coronary syndrome

KW - ADP receptor P2Y

KW - Cytochrome P450

KW - Dual antiplatelet treatment

KW - Pharmacogenetics

KW - Polymorphism

KW - Residual platelet reactivity

UR - http://www.scopus.com/inward/record.url?scp=38449103046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449103046&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e3282f1b2be

DO - 10.1097/FPC.0b013e3282f1b2be

M3 - Article

C2 - 18004210

AN - SCOPUS:38449103046

VL - 17

SP - 1057

EP - 1064

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 12

ER -